ResearcherInstitute of Cancer ResearchActive in the last 2 years

Jessica Kristine Nelson

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113642119. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 3

SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09574-y ↗
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Co-author DOI 10.1038/s41467-022-29684-9 ↗
GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Co-author DOI 10.1038/s41586-022-04888-7 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Axel Behrens · 3 shared papers, 2022–2025 · strength 0.43
Anguraj Sadanandam · 2 shared papers, 2022–2025 · strength 0.31
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Linxiang Lan · 2 shared papers, 2022–2025 · strength 0.31
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Huafu Li · 2 shared papers, 2022–2025 · strength 0.31
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Theodore Evan · 2 shared papers, 2022 · strength 0.24
- Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9 ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Yoh Zen · 2 shared papers, 2022 · strength 0.24
- Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9 ↗
- Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7 ↗
Tingzhuang Yi · 1 shared paper, 2025 · strength 0.19
- Paper SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. DOI 10.1038/s41586-025-09574-y ↗
Andreas A. Prachalias · 1 shared paper, 2022 · strength 0.12
- Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9 ↗
Debashis Sarker · 1 shared paper, 2022 · strength 0.12
- Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.